Income Statement (TTM)
Vivoryon Therapeutics N.V. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 11 | 11 | 11 | 0 | -2 | -4 | -4 | -4 | -2 |
| Change (%) | 0.00 | 0.00 | 0.00 | -100.00 | -∞ | 100.00 | -0.00 | -0.00 | -50.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | 0 | 2 | 2 | 2 | 1 | -0 | -1 | -1 | -1 | -0 |
| Change (%) | 221.52 | 0.00 | 0.00 | -31.10 | -124.28 | 100.00 | -0.00 | -0.00 | -50.00 | |
| % of Revenue | 4.53 | 14.58 | 14.58 | 14.58 | 14.50 | 14.50 | 14.50 | 14.50 | 14.50 | |
| Gross Operating Profit | 10 | 9 | 9 | 9 | -1 | -2 | -3 | -3 | -3 | -2 |
| Change (%) | -10.52 | 0.00 | 0.00 | -111.76 | 43.15 | 100.00 | -0.00 | -0.00 | -50.00 | |
| % of Revenue | 95.47 | 85.42 | 85.42 | 85.42 | 85.50 | 85.50 | 85.50 | 85.50 | 85.50 | |
| SG&A | 4 | 5 | 5 | 5 | 7 | 10 | 9 | 8 | 7 | 7 |
| Change (%) | 13.33 | -0.30 | -0.30 | 54.02 | 40.93 | -12.38 | -12.40 | -6.19 | 3.08 | |
| % of Revenue | 37.29 | 42.26 | 42.14 | 42.01 | -542.29 | -237.57 | -208.12 | -195.25 | -402.51 | |
| R&D | 17 | 17 | 18 | 19 | 20 | 17 | 18 | 20 | 22 | 18 |
| Change (%) | 4.12 | 4.62 | 4.41 | 2.36 | -15.31 | 6.72 | 11.48 | 10.30 | -17.59 | |
| % of Revenue | 155.72 | 162.13 | 169.62 | 177.10 | -913.07 | -487.21 | -543.14 | -599.06 | -987.40 | |
| OpEx | 21 | 24 | 24 | 25 | 28 | 26 | 25 | 26 | 28 | 25 |
| Change (%) | 10.87 | 3.37 | 3.26 | 9.53 | -6.27 | -2.34 | 3.80 | 5.95 | -11.13 | |
| % of Revenue | 197.44 | 218.91 | 226.29 | 233.67 | -1,426.66 | -696.60 | -723.08 | -766.13 | -1,361.74 | |
| Operating Income | -10 | -13 | -14 | -14 | -28 | -28 | -29 | -30 | -31 | -26 |
| Change (%) | 22.03 | 6.21 | 5.84 | 91.47 | 0.30 | 4.36 | 3.32 | 5.23 | -15.62 | |
| % of Revenue | -97.44 | -118.91 | -126.29 | -133.67 | 1,526.66 | 796.60 | 823.08 | 866.13 | 1,461.74 | |
| Interest Expense | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | |
| Change (%) | 8.33 | 7.69 | 1,912.50 | -91.66 | 19.15 | -3.57 | -3.70 | -4.81 | ||
| % of Revenue | -0.22 | -0.24 | -0.26 | 2.60 | 1.55 | 1.49 | 1.44 | 2.73 | ||
| Net Income | -12 | -13 | -13 | -14 | -26 | -27 | -28 | -30 | -31 | -26 |
| Change (%) | 9.42 | 3.60 | 3.48 | 89.90 | 6.02 | 3.76 | 5.02 | 4.78 | -17.02 | |
| % of Revenue | -107.44 | -117.57 | -121.80 | -126.04 | 1,509.14 | 782.93 | 822.20 | 861.46 | 1,429.64 | |
Source: Capital IQ
